Covid-19 Archives - Page 2 of 5 - Halberd Corporation

Mar 9 2021

Halberd Corporation’s CEO Interviewed on “The Stock Day Podcast” – Focus on Halberd’s New 20x Affinity Neutralizing SARS-COV-2 Antibody

By Admin|2021-03-08T20:35:16-05:00March 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...

Feb 16 2021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By Admin|2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens. The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...

Feb 1 2021

Halberd Corporation’s CEO Interviewed on The Stock Day Podcast and on MoneyTV

By Admin|2021-01-31T19:36:34-05:00February 1st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 1, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly, and on MoneyTV, hosted by Don Baillargeon. In each interview, Mr. Hartman reviewed the company’s progress on developing SARS-CoV-2 spike protein antibodies which could be ...

Jan 28 2021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

By Halberd|2021-01-28T08:45:25-05:00January 28th, 2021|Featured, Investor News, News|0 Comments

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, ...

Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By Admin|2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of nutritional supplements is based on numerous ...

Jan 12 2021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

By Admin|2021-01-11T19:57:47-05:00January 12th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021. Halberd was noted to be working in a different direction from the vaccine producers. ...

Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By Admin|2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is ...

Dec 14 2020

Halberd Corp. Research Yields Potent SARS-CoV-2 Antibody

By Admin|2020-12-13T17:40:49-05:00December 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By Admin|2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|0 Comments

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By Admin|2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...

Previous 123 Next